Home › Therapeutic areas › Oncology › Ovarian Cancer

Ovarian Cancer (17 companies)

Companies with an active program in Ovarian Cancer.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ANIX Anixa Biosciences Oncology 2 Phase 1 $92.8M 3
AVBP ArriVent BioPharma Oncology 1 Phase 3 $553M 7
BCTX BriaCell Therapeutics Oncology 1 Phase 3 $30.7M 8
CGEN Compugen Oncology 2 Phase 3 $191M 7
CBIO Crescent Biopharma Oncology 1 Phase 2 $507M 10
EIKN Eikon Therapeutics Oncology 2 Phase 2 $279M 13
GNLX Genelux Oncology 1 Phase 3 $96.1M 3
IDYA IDEAYA Biosciences Oncology 1 NDA Submitted $2.65B 15
IMTX Immatics Oncology 1 Phase 3 $958M 8
IMCR Immunocore DermatologyInfectious Disease+2 1 Approved $1.44B 12
IMNM Immunome Oncology Rare 1 NDA Submitted $2.03B 9
PMVP PMV Pharmaceuticals Oncology 1 Phase 2 $92.2M 7
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 $3.90B 9
VSTM Verastem Oncology 1 Approved $934M 5
XNCR Xencor ImmunologyNeurology+1 Rare 2 Approved $2.59B 28
ZNTL Zentalis Pharmaceuticals Oncology 1 Phase 3 $146M 1
ZYME Zymeworks OncologyRespiratory 2 Approved $1.78B 12